This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. The post Imugene HER2 vaccine hits target in stomach cancer trial appeared first on.
A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. percent with chemotherapy. The cancer vaccine offered an overall survival of 11.1 months for chemotherapy.
Chemotherapy can save people from cancer, but the side effects can wreak havoc on their bodies for months or years. Trade-offs in medicine can be harsh, even when clearly necessary. These trade-offs aren’t limited to the clinical world. They are also part of research.
A BioNTech-led Phase I trial demonstrated preliminary evidence that adjuvant autogene cevumeran, a personalised mRNA neoantigen vaccine, in combination with atezolizumab (Genentech) and mFOLFIRINOX can induce substantial T cell activity in pancreatic ductal adenocarcinoma (PDAC). Can an mRNA vaccine stimulate T cell response?
Luckily, there’s a shot to help prevent it: Shingrix, the shingles vaccine. The Shingrix vaccine triggers the immune system to respond to the varicella virus and suppress the outbreak of shingles,” says David Cutler , MD, a family medicine physician at Providence Saint John’s Health Center in Santa Monica, California.
A lymph node-targeted cancer vaccine has shown potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers in patients who have had surgery, according to a Phase I trial led by US researchers. Patients were given no more than 10 doses of the ELI-002 cancer vaccine targeted toward KRAS G12D and G12R mutations. “It
The idea of cancer vaccines is not new, but Dr Victoria Kunene, consultant medical oncologist at Queen Elizabeth Hospital Birmingham, UK, is leading the charge in their latest iteration: personalised preventative and therapeutic mRNA vaccines against colorectal cancer.
Chemotherapy leaves a person fatigued and nauseated. Treatments for sickle cell anemia can lead to infertility, and even routine vaccines sometimes have you nursing a sore arm for days. It’s common for patients and physicians to decide whether a treatment is worth it by weighing the health benefits against the side effects.
Pharmacist Dr João Gonçalves PhD considers the real-world evidence of a recent study demonstrating the feasibility and efficacy of a personalised peptide vaccine for glioblastoma – one of the most malignant primary brain tumours in adults.
It is the eighth vaccine recommended in the European Union (EU) for COVID-19. The committee recommended granting a paediatric-use marketing authorisation (PUMA) for Pedmarqsi (sodium thiosulfate) for preventing ototoxicity induced by cisplatin chemotherapy. Cisplatin is a chemotherapy used to treat several types of cancer.
Pfizer has announced it is expanding its ‘An Accord for a Healthier World’ initiative, to include its full portfolio of medicines and vaccines for which Pfizer has global rights. The initial not-for-profit offering provided access to all its patented medicines and vaccines available in the US or European Union (EU) to 1.2
Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.
Evusheld (tixagevimab and cilgavimab) was cleared by the FDA towards the end of 2021, becoming the first antibody to be authorised for prevention of COVID-19 infection, and it rapidly found use among people with compromised immune systems, such as cancer chemotherapy and organ-transplant patients.
The medicines – which include insulin, oral diabetes agent glibenclamide and cancer chemotherapy oxaliplatin – will be sold under a new Impact brand and are all classed as essential medicines by the World Health Organisation (WHO). ” The post Sanofi makes low-cost medicines pledge for low-income countries appeared first on.
Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.
Researchers predicted Artemis-SCID patients would need less chemotherapy to prepare their marrow for transfusion when their own cells were being used, so only 25 percent of a full dose of busulfan was administered. The second outcome was T-cell reconstitution at 12 months, a measurement of the strength of the immune system.
As the prevalence of cancer is continuing to increase, the role of the pharmacist becomes more important to help prevent any drug-drug interactions between these medications and chemotherapy and counseling patients on the proper use and appropriateness of certain OTC products. Vaccinations can be given before, during, and after chemotherapy.
The CHMP also recommended an extension of the use of the smallpox vaccine Imvanex (live modified vaccinia virus Ankara) to include protecting adults from monkeypox and disease caused by vaccinia virus. Rubraca referral outcome. The CHMP also recommended approving a new manufacturing site for the finished product in Madrid, Spain.
The US regulator has cleared the tyrosine kinase inhibitor (TKI) as a second-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumours have EGFR exon20 insertion mutations, after first-line chemotherapy.
Early-stage cervical cancer patients achieve good recovery through surgery and concurrent chemotherapy, but treatment options are scarce for those with recurrent metastatic cervical cancer. months, combination treatment with Libtayo and chemotherapy significantly lowered the risk of death by 34% in the study cohort. In both the PD-L1?1%
Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The results were published in the New England Journal of Medicine.
The group adopted a positive opinion for Tremelimumab AstraZeneca (tremelimumab), to treat metastatic non-small cell lung cancer (NSCLC) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy. The committee recommended to extend the use of original Spikevax vaccine and Spikevax bivalent Original/Omicron BA.1
The FDA now says it will fast track review of DKN-01 as a second-line therapy for DKK-positive G/GEJ cancers after prior fluoropyrimidine- and platinum- containing chemotherapy as well as anti-HER2 drugs if those have been deemed appropriate.
GSK decided to stop enrolling patients on the phase 2 INDUCE-3 trial, discontinuing treatment with feladilimab and has also axed the INDUCE-4 phase 2 trial, testing feladilimab versus placebo in combination with Keytruda and chemotherapy. billion signed with Germany’s Merck KGaA.
We also highlight our members' perspectives on health outcomes, oral oncolytics and vaccination recommendations. In a second session, he reviewed the latest updates on vaccines for meningococcal disease, human papillomavirus, and tetanus, diphtheria, and pertussis, among others. Learn more about the summit and PQA Convenes t below.
How do you envision microbiome therapies complementing existing cancer treatments, such as chemotherapy and immunotherapy? He has also held the role of Vice President and Therapeutic Area Head, Vaccine Clinical Research at Merck & Co. What will most impact the future development of microbiome therapies?
It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. months in patients treated with chemotherapy. In the 500 patient trial, patients treated with Trodelvy lived for a median of 12.1 months, compared with 6.7
A phase 3 trial of the PD-1 inhibitor in cervical cancer patients who had progressed after first-line chemotherapy has been stopped early after an interim look at the data showed that the drug cut mortality by 31% compared to second-line chemo. The median overall survival with Libtayo (cemiplimab) was 12 months, compared to 8.5
Even past the second wave, as vaccines become available, healthcare systems will not return rapidly to pre-pandemic capacities, let alone deliver more than that capacity. The pharmaceutical industry has risen magnificently to the challenge of COVID-19, in terms of treatment and vaccine development.
Recent successes in FDA approvals of antibody–drug conjugates (ADCs), RNA therapeutics and the UK’s regulatory leadership in coronavirus vaccines show that complex medicines are having a global impact. But the benefits of complex medicines go far beyond those we have seen with these vaccines.
Chemotherapy, the current standard of care for cancer treatment, can be harmful to both the cancer cells and the body’s healthy cells. ” Moderna has also created a personalised cancer vaccine, a similar idea where the vaccine is built against the specific cancer one has in the body.
People who have received flu vaccination usually experience less severe symptoms. Can the flu vaccine shorten the duration of illness? The CDC recommends that all persons 6 months and older get the annual flu vaccine.
IPH5201 is being investigated in a Phase II trial, MATISSE, in combination with durvalumab (anti-PD-L1) and chemotherapy, in patients with resectable early-stage NSCLC. Innate Pharma also developing IPH5201 in collaboration with AstraZeneca.
Keytruda is indicated in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. It is also indicated for the treatment of metastatic transitional (urothelial) tract cancer and gastric cancer.
New responsibilities, new arenas The potential for in-hospital manufacturing is further developing due to the new responsibilities assigned to hospital pharmacy staff, such as centralised preparation of chemotherapies and drugs for clinical trials, extemporaneous production of radiopharmaceuticals and cellular therapies, to name but a few.
In cats, prednisolone is used as an add-on treatment to chemotherapy drugs or as a palliative treatment for advanced cancers. Live vaccines should be avoided because prednisone and prednisolone weaken the immune system. The use of prednisone is discouraged. Cats on insulin may require higher doses of insulin.
Indeed, efforts to contain the virus in the absence of a vaccine have been based on the use of health data, giving the wider public an awareness of its importance and power within the health system. The COVID-19 pandemic has raised awareness about many facets of the NHS, including its capabilities to produce and leverage health data.
These treatments have yielded huge gains, with improved overall survival, fewer side-effects and improved patient quality of life; far better than the “sledgehammer” approach of chemotherapy. By improving sanitation and with the use of vaccines, we were able to reduce infections. Shah SC, Kayamba V, Peek RM, Jr., Heimburger D.
Prednisone is usually used as an add-on treatment to chemotherapy drugs or as a palliative treatment for advanced cancers. Live vaccines should be avoided because prednisone weakens the immune system. Of the lymphatic cancers, lymphoma is common, representing about 15% to 20% of cancers diagnosed in dogs every year.
People taking Enbrel can usually get vaccinations, but they should avoid live vaccines. Some studies suggest that Enbrel might slightly lower the body’s response to certain vaccines, like the pneumococcal vaccine. Similarly, live vaccines should also be avoided with Cosentyx due to similar safety concerns.
The narrower label for Zejula (niraparib) means it can only be used as second-line maintenance therapy after platinum-based chemotherapy in patients with these cancers whose tumours carry a germline BRCA mutation – around 15% of the population. The post GSK hits another oncology hurdle as Zejula use is limited again appeared first on.
In England for instance, the introduction of a biosimilar to prevent neutropenia in patients undergoing chemotherapy, resulted in a number of Strategic Health Authorities reassessing their guidance relating to this medicine.
There’s potential for combination drugs, paving the way for less toxic chemotherapy-free cancer drugs. It has brought a lot of good things working together and networking has led to unbelievable successes,” he added, noting the rapid development of vaccines by companies such as Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University.
The Nature publication touches on this in the case of platinum-based chemotherapy. There, copy number changes can be used to differentiate between patients who respond to platinum chemotherapy and those who do not, explains Markowetz. At the moment, high mutational burden can be used to determine response to immunotherapies.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content